ONCT - New data on lead drug propels Oncternal Therapeutics up 78%

Thinly traded nano cap Oncternal Therapeutics ([[ONCT]] +78.1%) rockets on a whopping 543x surge in volume in apparent response to the release of an ASH abstract detailed updated results from an ongoing Phase 1/2 clinical trial evaluating lead candidate cirmtuzumab, combined with AbbVie and J&J's Imbruvica (ibrutinib), in patients with relapsed/refractory (r/r) mantle cell lymphoma ((MCL)) or treatment-naïve ((TN)) or r/r chronic lymphocytic leukemia ((CLL)).As of April 30, there were 12 evaluable MCL patients and 34 CLL (12 TN/22 r/r) patients enrolled in the dose-escalation phase.The overall response rate ((ORR)) in the MCL participants was 83% (n=10/12), including seven (58%) complete responders, three partials and two with stable cancer implying a disease control rate ((DCR)) of 100%. Median follow-up was 8.3 months and median progression-free survival ((PFS)) was 17.5 months.The ORR in CLL patients was 88% (n=30/34), including 92% (n=11/12) in the TN group and 86% (n=19/22) in r/r group, but only

For further details see:

New data on lead drug propels Oncternal Therapeutics, up 78%